Ares Life Sciences

Ares Life Sciences targets established European mid-market healthcare companies in pharmaceutical services, medical technology, specialty pharmaceuticals, and digital health. The office typically seeks control or co-control positions with equity checks exceeding €20 million. Its holdings have included businesses with strong regulatory barriers and recurring revenue models, such as contract manufacturing and diagnostic testing platforms.

No. Ares Life Sciences is a single-family office headquartered in London and has no corporate relationship with Ares Management, the publicly traded alternative asset manager based in Los Angeles. The shared name is coincidental. Ares Life Sciences does not manage third-party capital or sponsor commingled funds.

Ares Life Sciences operates with a proprietary sourcing model drawn from the principal's network in European healthcare and life sciences. The office relies on direct relationships with founders, family-owned healthcare businesses, and sector-specialist intermediaries rather than broad auction processes. This concentrated sourcing approach reflects its small team and permanent-capital mandate.

No, the single-family office structure imposes no fixed holding period. Ares Life Sciences can hold assets indefinitely, which aligns with the extended regulatory and development timelines common in healthcare investing. This contrasts with closed-end private equity funds, which typically face pressure to realize returns within a 10-year fund life.

Ares Life Sciences deploys the private capital of a single European family, whose wealth origin has not been publicly disclosed. The office does not solicit or accept external investor commitments. This permanent-capital base allows the firm to operate without redemption constraints or formal fundraising cycles.